Rapamycin resistant cells
AssigneeSeattle Children's Hospital (dba Seattle Children's Research Institute)
InventorsAndrew M. Scharenberg, David J. Rawlings, Karen Sommer, Samuel West, Yuchi Chiang Honaker, Ryo Takeuchi
Life of this patent
Estimating the term…
Abstract
The present application relates to, inter alia, compositions including proteins for expression in host cells to render them resistant to rapamycin. The application further relates to methods of using the proteins, cells, and compositions disclosed therein for modulating cell signaling and for selective expansion of cells.
Claims20
(canceled)
A viral vector capable of transducing a mammalian cell, the viral vector comprising a nucleic acid comprising a polynucleotide sequence encoding an FK506-binding protein (FKBP)-rapamycin-binding (FRB) domain polypeptide, wherein the FRB domain polypeptide is a naked FRB domain polypeptide that is capable of being intracellularly expressed and capable of binding rapamycin, and wherein the naked FRB domain polypeptide comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO:
- 1.
A viral vector capable of transducing a mammalian cell, the viral vector comprising:
- a) a first polynucleotide encoding a first chemically inducible signaling complex (CISC) component comprising a first extracellular binding domain comprising a FK506-binding protein (FKBP) domain, a first transmembrane domain, and a first signaling domain;
- b) a second polynucleotide encoding a second CISC component comprising a second extracellular binding domain comprising a FKBP-rapamycin-binding (FRB) domain, a second transmembrane domain, and a second signaling domain;
- and
- c) a third polynucleotide encoding a naked FKBP-rapamycin binding (FRB) domain polypeptide, wherein the naked FRB domain polypeptide is capable of being intracellularly expressed, and capable of binding rapamycin.
Dependencies are inferred from the claim text.